Smokers of menthol and nonmenthol cigarettes exhibit similar levels of biomarkers of smoke exposure

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 2, 2009, Pages 622-629

  Daniel Heck, J ^a  

^a LORILLARD TOBACCO COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTANONE; 3' HYDROXYCOTININE; 4 (N NITROSOMETHYLAMINO) 1 (3 PYRIDYL) 1 BUTANOL; BIOLOGICAL MARKER; BUTANOL; CARBOXYHEMOGLOBIN; COTININE; GLUCURONIDE; MENTHOL; NICOTINE; NITROSAMINE 4 (N NITROSOMETHYLAMINO) 1 (3 PYRIDINYL) 1 BUTANONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CIGARETTE SMOKING; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY TRACT CANCER; TOBACCO DEPENDENCE; URINALYSIS;

ADULT; BIOLOGICAL MARKERS; CARBOXYHEMOGLOBIN; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; LINEAR MODELS; MALE; MENTHOL; MIDDLE AGED; NICOTINE; NITROSAMINES; SMOKING;

EID: 60549102291     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0550     Document Type: Article

References (46)

1. World Health Organization. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 83 Tobacco Smoke and Involuntary Smoking. 2002.
2. U.S. Department of Health & Human Services. The health consequences of smoking: a report of the surgeon general. Atlanta, GA: Author, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health. 2004.
3. Parascandola M. Lessons from the history of tobacco harm reduction: the National Cancer Institute's Smoking and Health Program and the ''less hazardous cigarette''. Nicotine Tob Res 2005;5:779-89.
4. Stratton K, Shetty P, Wallace R, Bondurant S, editors. Clearing the smoke: assessing the science base for tobacco harm reduction. Institute of Medicine. Washington (DC): National Academies Press; 2001.
5. Hatsukami DK, Benowitz NL, Rennard SI, Oncken C, Hecht SS. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 2006;8:600-22. Corrected and republished from: Nicotine Tob Res 2006;8(2):169-91.
6. Life Sciences Research Office. Lewis KD, editor. Exposure assessment in the evaluation of potential reduced-risktobacco products. Bethesda (MD): Life Sciences Research Office, Inc.; 2007.
7. Bernert JT, Jain RB, Pirkle JL, Wang L, Miller BB, Sampson EJ. Urinary tobacco-specific nitrosamines and 4-aminobiphenyl hemoglobin adducts measured in smokers of either regular or light cigarettes. Nicotine Tob Res 2005;7:729-38.
8. Melikian AA, Djordjevic MV, Chen S, Richie J, Jr., Stellman SD. Effect of delivered dosage of cigarette smoke toxins on the levels of urinary biomarkers of exposure. Cancer Epidemiol Biomarkers Prev 2007;16:1408-15.
9. Mendes P, Kapur S, Wang J, Feng S, Roethig H. A randomized, controlled exposure study in adult smokers of full flavor Marlboro cigarettes switching to Marlboro lights or Marlboro ultra lights cigarettes. Regul Toxicol and Pharmacol 2008;51:295-305. Epub 2008 May 11.
10. Office of Applied Studies. Results from the 2005 National Survey on Drug Use and Health: National findings (DHHS Publication No. SMA 06-4194, NSDUH Series H-30). Rockville (MD): Substance Abuse and Mental Health Services Administration; 2006. Available from: http://www.oas.samhsa.gov.
11. ClarkPI, Gardiner PS, Djordjevic MV, Leischow SJ, Robinson RG. Menthol cigarettes: setting the research agenda. Nicotine Tob Res 2004;6:S5-9.
12. Hebert JR, Kabat GC. Menthol cigarette smoking and oesophageal cancer. Int J Epidemiol 1989;18:37-4.
13. Kabat GC, Hebert JR. Use of mentholated cigarettes and lung cancer risk. Cancer Res 1991;51:6510-3.
14. Kabat GC, Hebert JR. Use of mentholated cigarettes and oropharyn-geal cancer. Epidemiology 1994;5:183-8.
15. Sidney S, Tekawa IS, Friedman GD, Sadler MC, Tashkin DP. Mentholated cigarette use and lung cancer. Arch Intern Med 1995;155:727-32.
16. Carpenter, CL, Jarvik ME, Morgenstern H, McCarthy, WJ, London SJ. Mentholated cigarette smoking and lung cancer risk. Ann Epidemiol 1999;9:114-20.
17. Friedman GD, Sadler M, Tekawa IS, Sidney S. Mentholated cigarettes and non-lung smoking related cancers in California, USA. J Epidemiol Community Health 1998;52:202-3.
18. Stellman D, Chen Y, Muscat E, et al. Lung Cancer riskin white and black Americans. Ann Epidemiol 2003;13:294-302.
19. Brooks DR, Palmer JR, Strom BL, Rosenberg L. Menthol Cigarettes and Riskof Lung Cancer. Am J Epidemiol 2003;158:609-16.
20. Pletcher MJ, Hulley BJ, Houston T, Kiefe CI, Benowitz N, Sidney S. Menthol cigarettes, smoking cessation, atherosclerosis, and pulmonary function: The coronary artery riskdevelopment in young adults (CARDIA) study. Arch Intern Med 2006;166:1915-22.
21. Murray RP, Connett JE, Skeans MA, Tashkin DP. Menthol cigarettes and health risks in Lung Health Study data. Nicotine Tob Res 2007;9:101-7.
22. Etzel CJ, Kachroo S, Liu M, et al. Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev Res 2008;1:255-65.
23. Hebert JR. Invited commentary: menthol cigarettes and riskof lung cancer. Am J Epidemiol 2003;158:609-16.
24. Werley MS, Coggins CRE, Lee PN. Possible effects on smokers of cigarette mentholation: a review of the evidence relating to key research questions. Regul Toxicol Pharmacol 2006;47:189-203.
25. U.S. Department of Health and Human Services. Tobacco use among U.S. racial/ethnic minority groups - African Americans, American Indians and Alaska Natives, Asian Americans and Pacific Islanders, and Hispanics: A Report of the Surgeon General. Atlanta: USDHHS Office of Smoking and Health; 1998.
26. National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. (September 20, 2007). The NSDUH Report: Cigarette Use among Blacks: 2005 and 2006. Rockville (MD): 2007.
27. Kozlowski LT, O'Connor RJ, Sweeney CT. Cigarette design. In: Risks associated with smoking cigarettes with low machine-measured tar and nicotine yields. NCI Smoking and Tobacco Control Monograph No 13. Bethesda: 2001.
28. Scherer G. Carboxyhemoglobin and thiocyanate as biomarkers of exposure to carbon monoxide and hydrogen cyanide in tobacco smoke. Exp Toxicol Pathol 2006;58:101-24.
29. Tricker AR. Biomarkers derived from nicotine and its metabolites: A Review. Beitr Tabakforsch Int 2006;22:147-75.
30. Cogliano V, Straif K, Baan R, Grosse Y, Secretan B, Ghissassi FE. WHO IARC. Smokeless tobacco and tobacco-related nitrosamines. Lancet Oncol 2004;5:708.
31. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002;23:907-22.
32. U.S. Federal Trade Commission. "Tar," nicotine, and carbon monoxide of the smoke of 1294 varieties of domestic cigarettes for the year 1998. Washington (DC): U.S. Federal Trade Commission; 2000.
33. Smith CJ, Guy TD, Stiles MF, et al. A repeatable method for determination of carboxyhemoglobin levels in smokers. Hum Exp Toxicol 1998;17:29-4.
34. St.Charles FK, Krautter GK, Dixon M, Mariner DC. A comparison of nicotine dose estimates in smokers between filter analysis, salivary cotinine, and urinary excretion of nicotine metabolites. Psychophar-macology (Berl) 2006;189:345-54.
35. Bailey B. A highly sensitive and specific analytical procedure for the determination of a tobacco specific nitrosamine, 4-(methylamino)-1-(3-pyridyl)- 1-butanol in human urine using molecular imprinted polymer extraction, hydrophilic interaction liquid chromatography and mass spectrometric detection. Nashville (TN): Proceedings of the 62nd Tobacco Science Research Conference; 2008. p. 19.
36. Benowitz NL, Herrera B, Jacob P. Mentholated cigarette smoking inhibits nicotine metabolism. J Pharmacol Exp Ther 2004;310: 1208-15.
37. Hecht SS, Murphy SE, Carmella SG, et al. Similar uptake of lung carcinogens by smokers of regular, light, and ultralight cigarettes. Cancer Epidemiol Biomarkers Prev 2005;14:693-8. Erratum in Cancer Epidemiol Biomarkers Prev 2006;15:1568. Dosage error in text.
38. Pickworth W B, Moolchan E T, Berlin I, Murty R. Sensory and physiologic effects of menthol and non-menthol cigarettes with differing nicotine delivery. Pharmacol Biochem Behav2002;71:55-61.
39. Patterson F, Benowitz N, Shields P, et al. Individual differences in nicotine intake per cigarette. Cancer Epidemiol Biomarkers Prev 2003;12:468-71.
40. O'Connor RJ, Ashare RL, Cummings KM, HawkLW. Comparing smoking behaviors and exposures from flavored and unflavored cigarettes. Addict Behav 2007;32:869.
41. Moldoveanu SC and St.Charles FK. Differences in the chemical composition of the particulate phase of inhaled and exhaled cigarette mainstream smoke. Beitrage Tabakforsch Int 2007;22:29-302.
42. Feng S, Plunkett S E, Lam K, et al. A new method for estimating the retention of selected smoke constituents in the respiratory tract of smokers during cigarette smoking. Inhal Toxicol 2007;19:169-79.
43. Perez-Stable EJ, Herrera B, Jacob P, Benowitz NL. Nicotine metabolism and intake in black and white smokers. J Am Med Assoc 1998;280:152-6.
44. National Cancer Institute. Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and Tobacco Control Monograph No 13. Bethesda (MD): U.S. Department of Health and Human Services, NIH, National Cancer Institute; 2001.
45. Hammond D, Fong GT, Cummings KM, O'Connor RJ, Giovino GA, McNeill A. Cigarette yields and human exposure: a comparison of alternative testing regimens. Cancer Epidemiol Biomarkers Prev 2006;15:1495-501.
46. Scherer G, Engl J, Urban M, Gilch G, Janket D, Riedel K. Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul Toxicol Pharmacol 2006;47:171-83.